HIV drugmakers ViiV, Gilead top 2018 pharma reputation survey
According to an annual patient group opinion report from PatientView, 41% thought the pharma industry’s reputation was “excellent” or “good” in 2018, and 53% of patient groups rated the industry as “excellent” or “good” for the making of high-quality products.
Among individual pharma company ratings, GlaxoSmithKline’s HIV arm, ViiV Healthcare, continued as No. 1 in 2018 among the 46 companies ranked. Its rival HIV drugmaker, Gilead Sciences, ranked No. 2, up one spot from 2017. In third place was Johnson & Johnson pharma unit Janssen, which moved up from fifth place.
Among the biggest movers in the survey, Takeda made the giant leap from No. 37 last year up to No. 7, which is attributed to its acquisition of Shire as well as concerted efforts to improve patient centricity. Another mover was Sanofi, which jumped up five places to No. 10.
